Volume 43, number S4: Buprenorphine and HIV Primary Care: Report of a Forum for Collaborative HIV Research Workshop
16th Nov 2006, 21:43 GMT
On 3–4 June 2004, in Washington, DC, the Forum for Collaborative HIV Research convened experts from academia, community and private practices, US government agencies, and industry to develop recommendations for increased uptake of buprenorphine integrated into human immunodeficiency virus (HIV) primary care, with special emphasis on Ryan White CARE Act–funded programs. Workshop participants evaluated knowledge gaps requiring research; barriers to integration at the patient, clinic, and systems level; policy and financing issues; and program impacts. Recommendations were developed for training, including medical school and post–medical school training of clinical teams as well as training of patients; for improving programs and services, including integration of opioid dependence and HIV infection into chronic disease models, providing flexible access to core and support services, and monitoring and evaluation of programs; for changes in policy supportive of program and services goals; for financing buprenorphine treatment by use of existing models of integrated treatment and merging funding streams at the local level; and for addressing research gaps, including cost-effectiveness research.
Latest news from Clin Infect Dis Latest Issue:
- Volume 43, number S4: Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
- Volume 43, number S4: Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
- Volume 43, number S4: The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
- Volume 43, number S4: A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
- Volume 43, number S4: Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States
- Volume 43, number S4: Buprenorphine Use: The International Experience
- Volume 43, number S4: Pharmacokinetic Interactions between Buprenorphine and Antiretroviral Medications
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine
- Volume 43, number S4: Interactions between Buprenorphine and Antiretrovirals. II. The Protease Inhibitors Nelfinavir, Lopinavir/Ritonavir, and Ritonavir
- Volume 43, number S4: Overcoming Policy and Financing Barriers to Integrated Buprenorphine and HIV Primary Care